Schizophrenia: all 3,539 studies
Page 34 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.
- A Comparative Study of New Medications for Psychosis in AdolescentsCompletedNCT00222495Not applicable
- Adjunctive Treatment for Decreasing Symptoms of SchizophreniaCompletedNCT00222235Phase 2/3
- The National Danish Schizophrenia ProjectStatus unknownNCT00221585
- Shared Decision Making for SchizophreniaCompletedNCT00220870Not applicable
- PREvent First Episode Relapse (PREFER)Status unknownNCT00220714Phase 4
- Effect of Bupropion on Smoking Behavior in Smokers With SchizophreniaCompletedNCT00218231Phase 2
- Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With SchizophreniaCompletedNCT00218218Phase 2
- Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar DisorderCompletedNCT00216723
- A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)CompletedNCT00216632Phase 4
- A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset PsychosisCompletedNCT00216580Phase 3
- A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone MicrospheresCompletedNCT00216528Phase 4
- Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant SchizophreniaTerminatedNCT00216281Phase 3
- D-Serine Monotherapy for SchizophreniaStatus unknownNCT00215917Phase 1/2
- Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete AdherenceCompletedNCT00215579Phase 4
- Seroquel on Glucose MetabolismCompletedNCT00214578Phase 4
- Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)CompletedNCT00212836Phase 3
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)CompletedNCT00212784Phase 3
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)CompletedNCT00212771Phase 3
- Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty AcidsTerminatedNCT00211562Phase 3
- Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)TerminatedNCT00211380Not applicable
- Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)TerminatedNCT00211302Not applicable
- A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With SchizophreniaCompletedNCT00210769Phase 3
- A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With SchizophreniaCompletedNCT00210717Phase 3
- A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00210691Phase 3
- A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With SchizophreniaCompletedNCT00210548Phase 3
- Abilify Therapy for Reducing Comorbid Substance AbuseCompletedNCT00208169Phase 4
- Seroquel Therapy for Substance Use Disorders Comorbid With SchizophreniaCompletedNCT00208143Phase 4
- Neurobiological and Neurocognitive Disturbances in First-episode SchizophreniaCompletedNCT00207064Not applicable
- Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?CompletedNCT00206986Not applicable
- Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode SchizophreniaCompletedNCT00206960Not applicable
- The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in SchizophreniaTerminatedNCT00206947Phase 2
- Clinical Estradiol Trial in Women With SchizophreniaCompletedNCT00206570Phase 2
- The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot StudyCompletedNCT00206557Phase 2
- Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With SchizophreniaCompletedNCT00206128Phase 3
- SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With SchizophreniaCompletedNCT00206115Phase 3
- Janssen - Glucose Regulation/Risp/OlanzCompletedNCT00205738Not applicable
- Pfizer/IVGTT/Ziprasidone/OlanzapineCompletedNCT00205725Not applicable
- Microglia Activation in SchizophreniaCompletedNCT00205608Phase 1
- Psychological Intervention for Persons in the Early Initial Prodromal StateStatus unknownNCT00204087Phase 3
- Early Pharmacological and Psychological Intervention for Late Prodromal States of PsychosisCompletedNCT00204061Phase 4
- Improving Work Outcome in People With Recent-onset SchizophreniaCompletedNCT00203788Phase 4
- Indicated Prevention of Psychotic Disorders With Low-dose LithiumCompletedNCT00202306Phase 4
- Efficacy and Safety Study of Aripiprazole to Treat SchizophreniaCompletedNCT00202007Phase 2
- Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic IllnessCompletedNCT00199940Phase 4
- Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in SchizophreniaSuspendedNCT00197483
- In-Patient Study In Schizophrenic PatientsCompletedNCT00197093Phase 1
- Bifeprunox in the Treatment of SchizophreniaCompletedNCT00193713Phase 3
- Bifeprunox in the Treatment of SchizophreniaCompletedNCT00193687Phase 3
- Entacapone Augmentation for SchizophreniaCompletedNCT00192855Not applicable
- AIMHI NT Relapse Prevention TrialStatus unknownNCT00192582Not applicable
- Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic TreatmentCompletedNCT00191555Phase 4
- Clozapine IM and Aggression in Schizophrenic PatientsWithdrawnNCT00189995Phase 3
- Magnetic Stimulation as a Treatment for Auditory Hallucinations in SchizophreniaStatus unknownNCT00186771Phase 4
- Continued Early Intervention for Recent-onset SchizophreniaTerminatedNCT00184509Phase 3
- The Immune System and Psychiatric DisordersCompletedNCT00184418
- Effects of Psychoeducation of Relatives to Patients With Serious Mental IllnessCompletedNCT00184379Not applicable
- Diabetes Prevention Program in Schizophrenia [DPPS]Status unknownNCT00182494Phase 4
- Cognition, Functioning and Quality of LifeCompletedNCT00182442Phase 4
- Treating Schizophrenia by Correcting Abnormal Brain DevelopmentActive, not recruitingNCT00179465Phase 3
- Olanzapine Versus Clozapine in Treatment Refractory SchizophreniaCompletedNCT00179231Not applicable
- Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar DisorderCompletedNCT00179062Not applicable
- Serotonin 1A Agonists and Cognition in SchizophreniaCompletedNCT00178971Phase 3
- Evaluation of QTc Interval by Continuous Holter ECG Recording in Antipsychotic Drug-treated Patients With SchizophreniaCompletedNCT00178958Not applicable
- Improving Outcome in Schizophrenia Through Identification of Genetic Risk FactorsCompletedNCT00178932Not applicable
- Usability of a Website for People With SchizophreniaWithdrawnNCT00177879Not applicable
- Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With PravastatinCompletedNCT00177580Phase 4
- L-carnosine for SchizophreniaCompletedNCT00177177Not applicable
- Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietyCompletedNCT00177008Phase 4
- Pregnenolone in the Management of Schizophrenia PatientsCompletedNCT00174889Phase 1
- Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With RisperidoneCompletedNCT00174200Not applicable
- The Quality of Life of Patients With Severe IllnessesStatus unknownNCT00173329
- A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)Status unknownNCT00173069
- The Establishment of the Early Intervention Program for Patients With SchizophreniaStatus unknownNCT00172770
- Measurement of Activity Participation for Persons With Schizophrenia Living in the CommunityCompletedNCT00172731
- Aggressive Acts Among Patients With SchizophreniaSuspendedNCT00172497
- Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative SymptomsCompletedNCT00169988Not applicable
- Aripiprazole Treatment of the ProdromeTerminatedNCT00169949Not applicable
- The Effect of a Weight Management Program During Treatment With OlanzapineCompletedNCT00169702Not applicable
- Repetitive Transcranial Magnetic StimulationCompletedNCT00169689Not applicable
- Clozapine Versus Haloperidol for Treating the First Episode of SchizophreniaTerminatedNCT00169091Phase 4
- Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant SchizophreniaCompletedNCT00169065Phase 4
- Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older PeopleCompletedNCT00169052Not applicable
- Clozapine Versus Chlorpromazine for Treatment-Unresponsive SchizophreniaTerminatedNCT00169039Phase 4
- Alcoholism and Schizophrenia: Effects of ClozapineTerminatedNCT00169026Phase 4
- Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot StudyCompletedNCT00167817Phase 4
- Cognitive Enhancement Therapy for Early-Stage SchizophreniaCompletedNCT00167362Phase 3
- Analysis of Genomic DNA Alterations in Familial SchizophreniaStatus unknownNCT00166738
- Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy SubjectsCompletedNCT00166322Not applicable
- Psychological Intervention for Relapse Prevention in First Episode SchizophreniaStatus unknownNCT00161408Not applicable
- Functional Brain Activation Patterns in Schizophrenia, Measured Before and After TreatmentCompletedNCT00161057
- An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit SymptomsCompletedNCT00161044Not applicable
- Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of SchizophreniaCompletedNCT00161031Not applicable
- New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant SchizophreniaCompletedNCT00161018Phase 3
- Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic PatientsCompletedNCT00159770Phase 3
- 12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic PatientsTerminatedNCT00159757Phase 4
- Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode SchizophreniaCompletedNCT00159133Phase 4
- Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode SchizophreniaCompletedNCT00159120Phase 4
- One Year Drug Treatment in First-Episode SchizophreniaCompletedNCT00159081Phase 4
- Reducing the Weight of Overweight Schizophrenia PatientsCompletedNCT00158366Not applicable
- Optimization of Acute Treatment in First Episode SchizophreniaStatus unknownNCT00157378Phase 4